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GENE SET ANALYSIS OF POST-LACTATIONAL MAMMARY GLAND INVOLUTION GENE 
SIGNATURES IN INFLAMMATORY AND TRIPLE NEGATIVE BREAST CANCER 
 
Arvind Bambhroliya, M.B.B.S., M.P.H. 
Supervisory Professor: Wendy Woodward, M.D. Ph.D. 
 
With each cycle of pregnancy and lactation, the mammary gland undergoes dramatic 
changes. Clarkson et al. (2004) and Stein et al. (2004) conducted a detailed analysis of these changes 
in the mouse mammary gland. Their results showed that tissue remodeling during post-lactational 
involution period mimics wound healing and tumorigenesis like pathological conditions. This 
indicates that post-lactational involution may create the microenvironment that initiates the 
development of precancerous mammary cells and promotes the progression of precancerous cells into 
cancer cells. Moreover, epidemiological studies have found that triple-negative (TN) breast cancer 
(BC) is associated with lower frequency and duration of breastfeeding compared to non-TN BC. 
Inflammatory breast cancer (IBC) accounts for approximately 1 - 5 % of all breast cancers and has 
significantly lower 5-year survival rates than those for non-IBC.  Approximately75% of the IBC 
samples belongs to the more aggressive subtypes like TN, HER2-enriched, and luminal B breast 
cancer. Similar to TN BC, TN IBC had been found to have significantly lower frequency and duration 
of breastfeeding compared to non-TN IBC. The higher frequency of aggressive forms of breast cancer 
in IBC and the association of TN BC and TN IBC with lower duration of breastfeeding indicate that 
molecular changes in the mammary gland during post-lactational involution might play roles in 
development of IBC and TN BC. We hypothesized that gene expression signatures of abrupt post-
lactational mammary gland involution correlate with IBC, TN IBC and TN non-IBC. We utilized 
gene expression data on multiple time-points of the mouse mammary gland development after abrupt 
weaning to create post-lactational mammary gland involution gene signatures using time-series 
cluster analysis. Using these gene expression signatures we performed gene set enrichment analysis 
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(GSEA) on human breast cancer gene expression data to identify specific gene expression signatures 
that are enriched in IBC compared to non-IBC and in TN compared to non-TN in IBC and non-IBC 
groups. We divided samples in training and validation sets to validate the results of GSEA. We 
identified 10 statistically significant time-varied gene expression patterns of post-lactational 
mammary gland involution. We found significant enrichment of one post-lactational involution gene 
signature in IBC compared to non-IBC. This enriched signature represents genes showing initial up-
regulation and later down-regulation during the involution process and significant overlap with genes 
up-regulated in vascular smooth muscle cells (VSMC) by c-Jun N-terminal protein kinase (JNK1). 
We identified 3 genes – Involucrin (IVL), Cluster of Differentiation 79B (CD79B), and leptin (LEP) – 
that were significantly enriched in IBC compared to non-IBC in both training and validation data sets 
and that are up-regulated in VSMC by JNK1. This data indicate that these genes might be playing 
roles in IBC development. 
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1 INTRODUCTION 
 
1.1 Background on Post-Natal Mammary Gland Development 
The mammary gland undergoes various stages of development during embryonic, pubertal, 
reproductive, and post reproductive periods of life. Involution is a term that has been described as the 
reverse of development [1] and, in the context of mammary gland development, describes the different 
forms of regression of mammary gland. Regression of the gland as a result of senility is described as a 
senile involution while post-lactational involution is the process by which the mammary gland returns 
from its lactating state to its non-lactating state [2]. It can occur in a gradual form (after gradual decrease 
in suckling) or in an abrupt form (after sudden cessation of milking or after sudden weaning of the young) 
[2]. The abrupt weaning of the young may mimic the shorter duration of breast-feeding in humans. Post-
lactational involution of the mammary gland is a complex multistage process which is characterized by 
regression of mammary gland epithelium through apoptosis and tissue remodeling [3]. Our knowledge of 
these stages is derived primarily from studies performed in a mouse model system, providing insight into 
the biology of post-lactational involution in the human mammary gland. Research on involution suggests 
that there are two phases of involution in mice [3]. The first phase lasts for about 48 hours and is 
reversible and characterized by apoptosis and alveolar cells detachment but no major morphological 
changes [3]. The second phase starts at 48 hours and is irreversible and characterized by collapse of 
alveoli, breakdown of extracellular matrix and activation of proteases [3]. By six days, most of secretary 
epithelium is removed and replaced by adipocytes [3]. Morphologically, mammary gland at the end of 
involution process looks similar to that of a virgin state mammary gland. Clarkson et al. [4] and Stein et 
al. [5] conducted gene expression profiling studies of these changes in the mouse mammary gland with 
the induction of forced weaning at the peak of lactation. Results of these two studies highlight distinct 
molecular characteristics between the virgin, pregnant, lactating and involuting states of the mammary 
gland. Various signaling pathways have been identified that regulate the transition from lactation to 
involution and the STAT family of proteins has been found to play a major role in this transition. These 
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results also show that tissue remodeling during post-lactational involution mimics wound healing and 
tumorigenesis like pathological conditions [6]. Inflammation and would healing responses have been 
found to be associated with tumor growth and progression [7].  An in-vitro study by McDaniel et al [8] 
found that mammary gland matrix from rats during the post-lactational involution stage promotes tumor 
cell invasion and metastasis. A study by Blanchard et al [9] identified genes that showed differential 
expression during the first day of involution in the mouse using microarray analysis and deregulation 
(down regulation) in breast cancer cell lines and breast tumor tissues. Stein et al [10] identified that genes 
showing differential expression at day 3 of mammary gland involution distinguished high and low 
metastatic breast cancer and these genes were associated with copper ion metabolism and with HIF-1 
promoter binding sites. Lyons et al showed that the involuting mammary microenvironment promotes the 
invasiveness of ductal carcinoma in-situ  (DCIS) cells and invasive tumors formed from DCIS cells were 
dominantly triple negative using a mouse model [11]. Also it has been studied that both luminal and 
myoepithelial lineages in mammary gland contain long-lived stem cells and pregnancy leads to a transient 
11-fold increase in these mammary stem cells [12, 13]. These results indicate that the deregulated 
involution may create the microenvironment that promotes tumor growth and progression.  
 
1.2 Background on Inflammatory Breast Cancer and Triple Negative Breast Cancer 
Breast cancer (BC) is the most common cancer and second leading cause of cancer mortality 
among women in the United States [14]. Breast cancer has been classified into five subtypes through gene 
expression profiling [15] with significant differences in epidemiological risk factors, therapeutic 
approaches and prognosis among subtypes [16]. These subtypes include luminal A, luminal B, human 
epidermal growth factor receptor 2 (HER2) overexpressing, basal-like, and claudin-low tumor subtypes 
[15, 17]. Clinically, a panel of immunohistochemical biomarkers is used as a surrogate for gene 
expression profiling to classify breast cancer subtypes. These biomarkers are estrogen receptor (ER), 
progesterone receptor (PR) and HER2. Breast cancer with absence of ER expression, PR expression and 
HER2 overexpression is termed as triple-negative breast cancer. Triple negative (TN) breast cancer is 
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enriched in the basal-like breast cancer subtype which was identified through gene expression profiling 
[18].  It accounts for approximate 15% of all breast cancer incidents and has the lowest survival rates 
among all subtypes of breast cancer [19]. Inflammatory breast cancer (IBC) is a distinct type of breast 
cancer which is characterized clinically by its rapid onset, erythematous, and edematous presentation of 
the breast and pathologically by tumor emboli in the dermal lymphatics [20]. It accounts for 
approximately 1 - 5 % of all breast cancers but at all stages has significantly lower 5-year survival rates 
than that for non-IBC [20-22]. Gene expression profiling has also identified similar molecular subtypes in 
IBC as those in non-IBC [23-25] and all molecular subtypes of IBC have been found to have a poor 
prognosis [26]. One of reproductive risk factors that have been found to be associated with increased risk 
of triple negative breast cancer is little-to-no breast feeding while having at least one pregnancy have been 
found to be protective for luminal A breast cancer [27]. Similar to TN BC, TN IBC has been found to 
have significantly lower frequency and duration of breastfeeding compared to non-TN IBC (ER or PR 
positive or Her2neu positive) [28].  
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1.3 Central Hypothesis and Specific Aims  
Studies in mice indicate that post-lactational involution after abrupt weaning mimics wound 
healing and tumorigenesis like pathological conditions [6] and involuting mammary microenvironment 
promotes the invasiveness of ductal carcinoma in-situ  (DCIS) cells [11]. Epidemiological studies indicate 
that lower duration of breast feeding is associated with increased risk of developing TN BC [27] and TN 
IBC [28]. Findings from these animal and epidemiological studies suggest that changes in the mammary 
gland during abrupt post-lactational involution might specifically play roles in the development of TN BC 
and TN IBC. Also, recent studies in mice suggest that mammary gland contains long-lived stem cells 
residing at the top of the hierarchy which undergoes extensive expansion during several cycles of 
pregnancy. Abrupt involution could leave persistent likely receptor negative stem cells increasing the 
chance of an initiating TN BC and TN IBC event. We hypothesize that gene expression signatures of the 
abrupt post-lactational involution stage of mammary gland development are enriched in IBC and TN 
breast cancer.  To test our underlying hypothesis, we proposed three specific aims.  
1. To identify gene expression signatures for the abrupt post-lactational involution stage of 
mammary gland development using gene expression data from post-natal mouse mammary gland 
development 
2. To evaluate whether gene expression signatures for the abrupt post-lactational involution stage of 
mammary gland development are enriched in IBC compared with non-IBC 
3.  To evaluate whether gene expression signatures for the abrupt post-lactational involution stage 
of mammary gland development are enriched in TN breast cancer compared with non-TN breast 
cancer   
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2 DEVELOPMENT OF INVOLUTION SPECIFIC GENE SIGNATURES 
 
2.1 Methods 
Gene Expression Dataset on Mouse Mammary Gland Involution 
Two major studies by Clarkson et al. [4] and Stein et al. [5] conducted time-series microarray 
experiments on mammary gland at various stages of pregnancy, lactation and involution and identified 
gene expression changes in post-natal mammary gland development.  In the study by Clarkson et al. [4] , 
genome wide expression profiles were measured with Affymetrix GeneChip MGU74ver2a arrays at the 
12 stages of adult mouse mammary gland development (virgin, 8 week; pregnancy days 5, 10 and 15; 
lactation days 0, 5 and 10; and involution hours 12, 24, 48, 72 and 96 after forced weaning). In the study 
by Stein et al. [5], gene expression profiles were measured at the 17 stages of adult mouse mammary 
gland development (virgin, 10 and 12 weeks; pregnancy days 1, 2, 3, 8.5, 12.5, 14.5 and 17.5; lactation 
days 1, 3 and 7; and involution days 1, 2, 3, 4 and 20 after forced weaning). The gene expression data for 
both studies can be downloaded from the webpage of the Mammary Apoptosis and Development Group 
at the University of Cambridge (http://www.path.cam.ac.uk/~madgroup/) and from the NCBI Gene 
Expression Omnibus (GSE12247) (http://www.ncbi.nlm.nih.gov/geo/).  
 
Preprocessing of Gene Expression Data 
Raw gene expression profiles were preprocessed using GCRMA analysis [29] with quantile 
normalization and probeset-level signals were summarized in log base 2 scale. We selected a custom Chip 
Definition File (CDF) MGU74Av2_Mm_ENTREZG version 18 for more accurate probe mapping to 
genome [30]. There are 7952 probe sets with a CDF MGU74Av2_Mm_ENTREZG version 18 
representing 7882 genes as per the annotation database available for a CDF 
MGU74Av2_Mm_ENTREZG version 18 at the BrainArray. After preprocessing gene expression data, 
further analysis were conducted using information available for 7882 probe sets representing 7882 genes 
with one probe set-one gene relationship. 
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Identification of Differentially Expressed Genes across Time Points 
Tests of differences in expression were performed with the limma package (version 3.22.1) [31] 
from the Bioconductor project. The limma package uses the moderated t-statistic. A total of 1055 genes 
were identified as the most significantly differentially expression genes across time points (q-value < 
0.05) with greater than two-fold changes in at least 1 pair comparing time points.  
 
Clustering Analysis of Time-Series Expression Data 
Ernst et al presented an algorithm specifically designed for clustering time-series expression data 
[32] and developed the Short Time-series Expression Miner (STEM) program for analysis of time-series 
gene expression data [33]. The STEM program was obtained from the website of the Systems Biology 
Group of the School of Computer Science of Carnegie Mellon University (http://gene.ml.cmu.edu/stem/). 
The STEM program works by first defining a set of representative model profiles corresponding to 
possible patterns of gene expression across the conditions that are examined in the experiment. Each gene 
is, then, assigned to the closest profile on the basis of correlation coefficients. The expected number of 
genes for each profile is also computed using random permutation, renormalization and assignment of 
original values for each gene to profiles with over 500 repeated permutations. This serves as a basis for 
the calculation of the statistical significance of each profile. Statistically significant profiles represent the 
dominant expression profiles in the data set. The parameters used for STEM clustering were set at 50 for  
a maximum number of model profiles, 3 for a maximum unit change between time points and 0.7 for a 
minimum correlation for clustering similar profiles. Significant expression profiles were identified with a 
false discovery rate (FDR) of 0.05. 
  
Ontology Analysis of Significant Clusters 
An ontology-based analysis was performed on genes of significant clusters identified through the 
STEM program. We used gene ontology (GO) annotations for mus musculus gene products (filename: 
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gene_association.mgi.gz) available from Mouse Genome Informatics (www.informatics.jax.org). 
Enrichment analysis for GO annotations was performed using a hypergeometric distribution in the STEM 
program and multiple hypothesis correction was done using a randomization test. P values were corrected 
with 500 randomizations and were considered significant with an FDR of <0.05 for gene-ontology 
enrichment analysis with the STEM program. 
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2.2 Results 
Differentially Expressed Genes across Time Points 
We used the limma package [31] from the Bioconductor project to identify differentially 
expressed genes across time points from lactation day 10 to involution day 4. We identified 1,055 
differentially expressed genes across time points from lactation day 10 to involution day 4 in the data 
from Clarkson et al. (2004). To verify our results, we conducted an analysis for differential expressed 
genes using data from Stein et al. (2004) and identified 2,567 genes differentially expressed across time 
points from lactation day 7 to involution day 20. 79% of genes identified as differentially expressed in the 
data from Clarkson et al. were also again identified as differentially expressed in the data from Stein et al. 
(2004). Figure 1 shows the Venn diagram of the overlap and discrepancies between genes differentially 
expressed in Clarkson et al. (2004) and Stein et al. (2004).  
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Figure 1: Venn diagram showing the overlap and discrepancies between genes differentially 
expressed in Clarkson et al. (2004) and Stein et al. (2004). 
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Clusters of Differentially Expressed Genes  
We used STEM algorithm developed by Ernst et al (28,29) to cluster genes identified as 
differentially expressed between last day lactation and last time point of involution. We used c=3 and 
m=50 for input parameters where c indicates units of change and m, the number of candidate profiles. 
This run significantly clustered 774 genes out of 1,055 genes (73.4 % of 1055 genes) differentially 
expressed genes. Table 1 lists patterns, size and p-value of significant clusters out of 50 possible cluster 
profiles. Patterns indicate the relative expression of genes in clusters compared to the lactation day 10 
levels. Figure 2 shows gene expression profiles for the ten significant clusters.  
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Table 1: Patterns, size and p-values of significant clusters identified through the STEM algorithm 
using data from Clarkson et al. 2004 
Cluster Pattern* Size P-Value Number of human orthologus genes identified 
#1 0,1,2,3,4,5 270 1.30E-234 256 
#2 0,-1,2,1,1,1 120 1.10E-54 118 
#3 0,-1,-2.-3.-4.-5 74 3.00E-26 69 
#4 0,-3,-1,-1,0,1 50 5.10E-11 47 
#5 0,3,0,-3,-3,-2 46 7.30E-08 43 
#6 0,-3,-4,-2,-3,-3 77 1.20E-07 76 
#7 0,-3,-4,-5,-6,-3 40 2.30E-05 39 
#8 0,-2,1,2,4,1 32 1.10E-04 31 
#9 0,2,1,0,2,5 39 5.70E-04 37 
#10 0,2,5,3,6,3 26 7.30E-04 26 
*Pattern indicates relative gene expression levels of lactation day 10 and involution days 0.5, 1, 2, 3 and 4 
days compared lactation day 10. 
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Figure 2: Relative gene expression profiles for the ten significant clusters identified through the 
STEM Clustering.  
Y-axis represents the relative gene expression levels of involution days 0.5, 1, 2, 3 and 4 days 
compared lactation day 10 in log2 scale. X-axis represents the time points (L10, lactation day 10; 
I12h, involution day 0.5; I24h, involution day 1; I48h, involution day 2; I72h, involution day 3; 
I96h, involution day 4). SOCS3, suppressor of cytokine signaling 3; IGF1, insulin-like growth factor 
1 (somatomedin C); STAT3, signal transducer and activator of transcription 3 (acute-phase 
response factor); TGFB3, transforming growth factor, beta 3; ATF4, activating transcription factor 
4; IGFBP5, insulin-like growth factor binding protein 5; MMP3, matrix metallopeptidase 3 
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Ontology Analysis for Significant Clusters 
We next conducted ontology analysis on genes of significant clusters identified through the 
STEM using GO annotations for mus musculus gene products available from the Mouse Genome 
Informatics to understand biologically relevant processes. Gene ontology enrichment showed that only 
Cluster 1 was statistically significantly enriched for the biological processes while few biological 
processes were enriched in the other clusters (Table 2).  
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Table 2: Results of ontology analysis for the STEM significant clusters 
Type Category ID Category Name 
# Genes 
Category 
STEM Clusters 
#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 
BP GO:0001568 
Blood vessel 
development 
394 0.002 NS NS NS NS NS NS NS NS NS 
BP GO:0001944 
Vasculature 
development 
415 0.004 NS NS NS NS NS NS NS NS NS 
BP GO:0002455 
Humoral immune 
response mediated by 
circulating 
immunoglobulin 
37 0.038 NS NS NS NS NS NS NS NS NS 
BP GO:0006082 
Organic acid 
metabolic process 
517 NS NS NS NS NS NS 0.054 NS NS NS 
BP GO:0006631 
Fatty acid metabolic 
process 
190 0.038 NS NS NS NS 0.048 NS NS NS NS 
BP GO:0006635 
Fatty acid beta-
oxidation 
37 0.038 NS NS NS NS NS NS NS NS NS 
BP GO:0006909 Phagocytosis 84 0.008 NS NS NS NS NS NS NS NS NS 
BP GO:0006950 Response to stress 1539 0.004 NS NS NS NS NS NS NS NS NS 
BP GO:0006952 Defense response 575 <0.001 NS NS NS NS NS NS NS NS NS 
BP GO:0006954 Inflammatory response 322 0.002 NS NS NS NS NS NS NS NS NS 
BP GO:0006955 Immune response 529 <0.001 NS NS NS NS NS NS NS NS NS 
BP GO:0009062 
Fatty acid catabolic 
process 
47 0.036 NS NS NS NS NS NS NS NS NS 
BP GO:0009605 
Response to external 
stimulus 
932 0.004 NS NS NS NS NS NS NS NS NS 
BP GO:0016042 Lipid catabolic process 130 0.018 NS NS NS NS NS NS NS NS NS 
BP GO:0019395 Fatty acid oxidation 54 0.026 NS NS NS NS NS NS NS NS NS 
BP GO:0019752 
Carboxylic acid 
metabolic process 
490 NS NS NS NS NS NS 0.036 NS NS NS 
BP GO:0019882 
Antigen processing 
and presentation 
60 0.008 NS NS NS NS NS NS NS NS NS 
BP GO:0030036 
Actin cytoskeleton 
organization 
279 0.038 NS NS NS NS NS NS NS NS NS 
BP GO:0030198 
Extracellular matrix 
organization 
129 0.004 NS NS NS NS NS NS NS NS NS 
BP GO:0032101 
Regulation of response 
to external stimulus 
344 0.014 NS NS NS NS NS NS NS NS NS 
BP GO:0032103 
Positive regulation of 
response to external 
stimulus 
144 0.046 NS NS NS NS NS NS NS NS NS 
BP GO:0032787 
Monocarboxylic acid 
metabolic process 
286 NS NS NS NS NS 0.05 NS NS NS NS 
BP GO:0034097 Response to cytokine 298 0.004 NS NS NS NS NS NS NS NS NS 
BP GO:0034341 
Response to 
interferon-gamma 
39 0.008 NS NS NS NS NS NS NS NS NS 
BP GO:0034440 Lipid oxidation 56 0.004 NS NS NS NS NS NS NS NS NS 
BP GO:0040012 
Regulation of 
locomotion 
435 0.048 NS NS NS NS NS NS NS NS NS 
BP GO:0042127 
Regulation of cell 
proliferation 
869 0.052 NS NS NS NS NS NS NS NS NS 
BP GO:0042221 Response to chemical 1573 NS NS NS NS NS NS NS NS 0.004 NS 
BP GO:0043062 
Extracellular structure 
organization 
129 0.004 NS NS NS NS NS NS NS NS NS 
BP GO:0043436 
Oxoacid metabolic 
process 
511 NS NS NS NS NS NS 0.05 NS NS NS 
BP GO:0044281 
Small molecule 
metabolic process 
1299 NS NS NS NS NS 0.006 0.012 NS NS NS 
BP GO:0044711 
Single-organism 
biosynthetic process 
700 NS NS NS NS NS 0.02 NS NS NS NS 
BP GO:0045087 
Innate immune 
response 
233 0.002 NS NS NS NS NS NS NS NS NS 
BP GO:0048514 
Blood vessel 
morphogenesis 
344 0.032 NS NS NS NS NS NS NS NS NS 
BP GO:0070887 
Cellular response to 
chemical stimulus 
1033 NS NS NS NS NS NS NS NS 0.024 NS 
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BP GO:1901605 
Alpha-amino acid 
metabolic process 
117 NS NS 0.052 NS NS NS NS NS NS NS 
BP GO:2000145 
Regulation of cell 
motility 
396 0.048 NS NS NS NS NS NS NS NS NS 
CC GO:0000502 Proteasome complex 53 NS <0.001 NS NS NS NS NS NS NS NS 
CC GO:0000932 
Cytoplasmic mrna 
processing body 
26 NS 0.02 NS NS NS NS NS NS NS NS 
CC GO:0005578 
Proteinaceous 
extracellular matrix 
183 <0.001 NS NS NS NS NS NS NS NS NS 
CC GO:0005581 Collagen trimer 51 0.004 NS NS NS NS NS NS NS NS NS 
CC GO:0005615 Extracellular space 694 <0.001 NS NS NS NS NS NS NS NS NS 
CC GO:0005783 Endoplasmic reticulum 747 NS NS NS NS NS 0.002 NS NS NS NS 
CC GO:0005838 
Proteasome regulatory 
particle 
11 NS <0.001 NS NS NS NS NS NS NS NS 
CC GO:0009986 Cell surface 473 0.026 NS NS NS NS NS NS NS NS NS 
CC GO:0012505 
Endomembrane 
system 
1633 NS NS NS NS NS 0.006 NS NS NS NS 
CC GO:0016021 
Integral component of 
membrane 
1967 NS NS NS NS NS 0.008 NS NS NS NS 
CC GO:0022624 
Proteasome accessory 
complex 
18 NS <0.001 NS NS NS NS NS NS NS NS 
CC GO:0031224 
Intrinsic component of 
membrane 
2045 NS NS NS NS NS 0.006 NS NS NS NS 
CC GO:0031982 Vesicle 1944 <0.001 <0.001 NS NS NS NS NS NS NS NS 
CC GO:0031988 
Membrane-bounded 
vesicle 
1828 <0.001 <0.001 NS NS NS NS NS NS NS 0.052 
CC GO:0043227 
Membrane-bounded 
organelle 
5489 NS NS NS NS NS NS NS 0.038 NS NS 
CC GO:0043230 Extracellular organelle 1534 <0.001 <0.001 NS NS NS NS NS NS NS 0.04 
CC GO:0044420 
Extracellular matrix 
part 
89 0.004 NS NS NS NS NS NS NS NS NS 
CC GO:0044421 
Extracellular region 
part 
1992 <0.001 <0.001 NS NS NS NS NS NS NS NS 
CC GO:0044444 Cytoplasmic part 3297 NS NS NS NS NS 0.048 NS NS NS NS 
CC GO:0065010 
Extracellular 
membrane-bounded 
organelle 
1534 <0.001 <0.001 NS NS NS NS NS NS NS 0.04 
CC GO:0070062 
Extracellular vesicular 
exosome 
1528 <0.001 <0.001 NS NS NS NS NS NS NS 0.038 
BP, biological process; CC; cellular components 
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Involution Specific Gene Signatures 
To develop the involution specific gene signatures for the conduct of gene set analysis on human 
IBC and non-IBC gene expression profiles, we identified human orthologus genes for genes of significant 
clusters identified through STEM. Orthologs data was downloaded from the ENSEMBL website 
(http://www.ensembl.org/biomart/martview) and orthologous genes were identified using ENSEMBL 
gene id.  Table 3 lists the number of human orthologous genes identified for each of 10 significant 
clusters.  
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Table 3: Involution Specific Gene Signatures through the STEM clustering using data from 
Clarkson et al. 2004 
STEM 
Cluster 
Pattern* 
# 
Genes 
Number of human orthologous genes identified 
Signature 
name 
#1 0,1,2,3,4,5 270 256 Inv1 
#2 0,-1,2,1,1,1 120 118 Inv2 
#3 0,-1,-2.-3.-4.-5 74 69 Inv3 
#4 0,-3,-1,-1,0,1 50 47 Inv4 
#5 0,3,0,-3,-3,-2 46 43 Inv5 
#6 0,-3,-4,-2,-3,-3 77 76 Inv6 
#7 0,-3,-4,-5,-6,-3 40 39 Inv7 
#8 0,-2,1,2,4,1 32 31 Inv8 
#9 0,2,1,0,2,5 39 37 Inv9 
#10 0,2,5,3,6,3 26 26 Inv10 
*Pattern indicates relative gene expression fold changes of lactation day 10 and involution days 0.5, 1, 2, 
3 and 4 days profiles compared lactation day 10. 
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3 GENE SET ANALYSIS OF INVOLUTION SPECIFIC GENE SIGNATURES 
 
3.1 Methods 
Gene Expression Dataset on IBC and non-IBC cases 
Gene expression data for IBC and non-IBC cases were obtained from the NCBI Gene Expression 
Omnibus (GSE22597) and the EBI ArrayExpress (E-MTAB-1006 and E-MTAB-1547) and collected 
through the World IBC Consortium [25]. These databases include the largest series of IBC samples ever 
reported and tumor samples were obtained from patients treated in three institutions: the Institut Paoli-
Calmettes (IPC, Marseille, France: 71 IBC and 139 non-IBC cases), the MD Anderson Cancer Center 
(MDA, Houston, TX, USA: 25 IBC and 58 non-IBC cases), and the General Hospital Sint-Augustinus 
(TCRU, Antwerp, Belgium: 41 IBC and 55 non-IBC cases) [25].  
 
Preprocessing of Gene Expression Data 
Raw gene expression profiles were preprocessed using GCRMA analysis [29] with quantile 
normalization and probeset-level signals were summarized in log base 2 scale. We selected a custom Chip 
Definition Files (CDFs) HGU133A_Hs_ENTREZG version 18 for preprocessing GSE22597 data and 
HGU133Plus2_Hs_ENTREZG version 18 for preprocessing E-MTAB-1006 and E-MTAB-1547 data 
[30]. There are 12,135 probe sets with a CDF HGU133A_Hs_ENTREZG version 18 with 12,064 probe 
sets representing 12,064 genes as per the annotation database available at the BrainArray. There are 
19674 probe sets with a CDF HGU133Plus2_Hs_ENTREZG version 18 with 19,544 probe sets 
representing 19544 genes as per the annotation database available at the BrainArray. After preprocessing 
gene expression data, all 3 data sets were merged using common informative probe sets (N= 12,129). To 
remove the batch effect, we used the removeBatchEffect function from the limma package from the 
Bioconductor [31]. This function fits a linear model to the data and removes the components due to the 
batch effects. The principal component analysis plots were generated prior and after removing the batch 
effect to verify the accuracy of the removeBatchEffect function (Figure 3). The final merged dataset 
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consisted of 388 samples (137 IBC cases and 251 non-IBC cases) with 12,129 probe sets with 12,063 
probe sets representing 12,063 genes with one probe set – one gene relationship. 
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Figure 3: Principal Component Analysis plots prior and after regression normalization to verify the 
removal of batch effect. 
 
 
  
22 
 
Involution Specific Gene Signatures 
Involution specific gene signatures were identified from the results of STEM cluster analysis 
conducted on post-natal mouse mammary gland development as described in Chapter 2. We identified 
orthologous genes for genes that were found to form significant clusters in STEM cluster analysis by 
using ENSEMBL gene id on the orthologous data downloaded from the ENSEMBL website. Involution 
specific gene signatures have also been reported in the study by Stein et al. 2009 [10]. We downloaded 
those signatures and identified orthologous genes for each signature and used them to evaluate their 
enrichment in IBC versus non-IBC and TN versus non-TN subtypes.  
 
Gene Set Enrichment Analysis (GSEA) of Involution Specific Signatures 
We used GSEA algorithm as mentioned in [34] to evaluate enrichment of involution specific gene 
signatures in IBC cases compared to non-IBC cases and TN BC cases compared to non-TN BC cases.  
We ranked genes in the GSEA using t-test and all other options in the GSEA kept as default.  
 
Training and Validation Data 
We divided the merged dataset into the training set to run the GSEA and into the validation set to 
validate the GSEA results for reproducibility. We used the stratified random sampling method with 
inclusion of information on IBC status, TN status and age at diagnosis (<50 years or >=50 years) to divide 
the merged dataset into the training and validation sets (Table 4).  
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Table 4: Final merged dataset and training and validation sets 
 
Total 
cases 
IBC* Non-IBC* 
Total TN Non-TN Total TN Non-TN 
Merged Dataset 388 137 20 101 251 34 197 
Training Set 195 68 10 50 127 18 99 
Validation Set 193 69 10 51 124 16 98 
IBC, inflammatory breast cancer; TN, triple-negative 
*15 cases in IBC and 20 cases in non-IBC groups did not have information available on TN status. 
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3.2 Results 
Results of GSEA of Involution Specific Signatures in IBC versus non-IBC 
Out of 10 gene signatures developed through the STEM clustering using data from Clarkson et al. 
(2004), 7 signatures were upregulated in the training set of IBC phenotype with 2 signatures significant at 
FDR < 25%.  In the validation set, we found that 9 gene signatures were upregulated in IBC phenotype  
with no signature significant at FDR < 25%.  Three signatures were upregulated in non-IBC phenotype 
with no gene signatures significant at FDR <25% in the training set (Table 5). In the validation set, 1 gene 
signature was upregulated in non-IBC phenotype with no gene signature significant at FDR <25% (Table 
5). When comparing the results in the training and validation sets, we found that 6 out of 10 gene 
signatures were upregulated in IBC in both training and validation sets with only 1 gene signature (Inv 5) 
significant at nominal p-value of 0.05 in both the training and validation sets. In the merged 3 breast 
cancer data sets, we found that 2 out of 10 gene signatures (Inv5 and Inv6) were significantly upregulated 
in IBC versus non-IBC phenotype  at nominal p-value of 0.05 (Table 6). Figure 4 represents the 
enrichment plot from the GSEA for Inv5 signature in IBC versus non-IBC and Table 7 shows the list of 
genes in Inv5 signature and genes enriched in IBC. For the involution specific signatures reported by 
Stein et al. (2009), we found that no gene signature was significantly enriched in IBC or non-IBC at FDR 
<25% or nominal p-value of 0.05 in both the training and validation sets (Table 5) or in the merged 3 
breast cancer data sets (Table 6).  
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Table 5:  GSEA results of involution-specific signatures in IBC versus non-IBC in the training and 
validation sets 
Gene 
Signature 
Results on Training Set Results on Validation Set 
Enriched 
in IBC 
vs non-
IBC 
Size ES NES 
Nominal 
p-value 
FDR 
q-
value 
Enriched 
in IBC vs 
non-IBC 
Size ES NES 
Nominal 
p-value 
FDR 
q-
value 
Involution specific signatures developed through STEM clustering using data from Clarkson et al. 2004 
Inv1 IBC 205 0.360 1.064 0.415 0.443 IBC 205 0.212 0.643 0.912 0.927 
Inv2 Non-IBC 100 -0.139 -0.552 0.933 0.976 IBC 100 0.169 0.674 0.849 1.000 
Inv3 Non-IBC 57 -0.299 -0.917 0.625 1.000 IBC 57 0.322 1.030 0.403 0.836 
Inv4 IBC 33 0.392 1.108 0.360 0.469 IBC 33 0.307 0.907 0.581 0.835 
Inv5 IBC 30 0.514 1.492 0.014 0.263 IBC 30 0.492 1.436 0.028 0.433 
Inv6 IBC 62 0.402 1.399 0.043 0.222 IBC 62 0.326 1.122 0.258 1.000 
Inv7 IBC 36 0.295 0.843 0.719 0.650 Non-IBC 36 -0.284 -0.810 0.790 0.709 
Inv8 Non-IBC 24 -0.294 -0.883 0.647 0.897 IBC 24 0.294 0.878 0.621 0.774 
Inv9 IBC 33 0.611 1.363 0.131 0.184 IBC 33 0.409 0.915 0.592 0.975 
Inv10 IBC 21 0.296 0.897 0.583 0.654 IBC 21 0.339 1.030 0.414 1.000 
Involution specific signatures reported in Stein et al. 2009 
S.C1 IBC 182 0.42 1.16 0.274 0.818 IBC 182 0.35 0.94 0.522 1 
S.C2 Non-IBC 205 -0.27 -0.78 0.737 0.746 Non-IBC 205 -0.2 -0.63 0.945 0.962 
S.C3 IBC 252 0.2 0.74 0.766 0.922 Non-IBC 252 -0.22 -0.81 0.695 1 
S.C4 IBC 258 0.18 0.74 0.753 0.832 Non-IBC 258 -0.29 -1.25 0.215 0.718 
S.C5.I3VL7 IBC 117 0.21 0.8 0.743 0.906 IBC 117 0.23 0.83 0.672 1 
S.C6 Non-IBC 100 -0.25 -0.94 0.534 0.905 Non-IBC 100 -0.26 -1 0.438 0.715 
S.C7 IBC 225 0.29 1.17 0.19 1 IBC 225 0.24 0.97 0.504 1 
S.C8 Non-IBC 153 -0.25 -1.01 0.413 1 IBC 153 0.29 1.17 0.171 1 
S.C9 Non-IBC 66 -0.25 -0.8 0.818 0.952 Non-IBC 66 -0.39 -1.24 0.149 0.365 
S.I1VL7 IBC 495 0.19 0.85 0.693 1 Non-IBC 495 -0.16 -0.7 0.962 1 
S.I2VL7 IBC 612 0.21 0.87 0.647 1 IBC 612 0.2 0.79 0.784 0.977 
S.I3VL7 IBC 648 0.2 0.83 0.708 0.968 IBC 648 0.19 0.75 0.836 0.779 
S.I4VL7 IBC 894 0.23 0.91 0.579 1 IBC 894 0.2 0.78 0.777 0.835 
ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate; IBC, inflammatory 
breast cancer 
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Table 6:  GSEA results of involution-specific signatures in IBC versus non-IBC in the merged 3 
breast cancer data sets 
Gene 
Signature  
Merged 3 breast cancer data sets 
IBC = 137 and  non-IBC = 251 
# Genes = 12064 
Enriched in IBC 
versus non-IBC  
Size  ES  NES  Nominal p-value  FDR q-value  
Involution specific signatures developed through STEM clustering using data from Clarkson et al. 2004  
Inv1  IBC  205  0.29  0.88  0.584  0.869  
Inv2  IBC  100  0.13  0.52  0.97  0.988  
Inv3  IBC  57  0.25  0.81  0.807  0.902  
Inv4  IBC  33  0.32  0.94  0.541  0.873  
Inv5  IBC  30  0.51  1.47  0.03  0.392  
Inv6  IBC  62  0.42  1.47  0.021  0.204  
Inv7  IBC  36  0.26  0.75  0.867  0.896  
Inv8  Non-IBC  24  -0.3  -0.92  0.573  0.541  
Inv9  IBC  33  0.54  1.22  0.279  0.407  
Inv10  IBC  21  0.43  1.34  0.122  0.298  
Involution specific signatures reported in Stein et al. 2009  
S.C1  IBC  182  0.4  1.08  0.379  0.614  
S.C2  Non-IBC  205  -0.25  -0.77  0.735  0.902  
S.C3  Non-IBC  252  -0.19  -0.72  0.783  0.849  
S.C4  Non-IBC  258  -0.21  -0.89  0.568  1  
S.C5.I3VL7  IBC  117  0.29  1.1  0.315  0.818  
S.C6  Non-IBC  100  -0.26  -0.99  0.48  1  
S.C7  IBC  225  0.28  1.13  0.26  1  
S.C8  Non-IBC  153  -0.22  -0.88  0.717  0.835  
S.C9  Non-IBC  66  -0.37  -1.21  0.189  0.847  
S.I1VL7  IBC  495  0.19  0.83  0.717  0.639  
S.I2VL7  IBC  612  0.21  0.87  0.671  0.798  
S.I3VL7  IBC  648  0.21  0.84  0.694  0.729  
S.I4VL7  IBC  894  0.23  0.9  0.591  0.882  
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Figure 4: Enrichment plots form GSEA for Inv5 signature for IBC versus non-IBC in the training 
and validation sets.  
IBC, inflammatory breast cancer; nIBC, non-Inflammatory breast cancer.  
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Table 7: List of genes in Inv5 signature and genes enriched in IBC versus non-IBC  
Gene 
Symbol 
Gene Name 
Enrichment in 
IBC (Training 
Set) 
Enrichment in 
IBC (Validation 
Set) 
CD79B 
CD79b molecule, immunoglobulin-associated 
beta 
Yes Yes 
IVL involucrin Yes Yes 
KIF2C kinesin family member 2C Yes Yes 
NOP2 
 
Yes Yes 
LDHB lactate dehydrogenase B Yes Yes 
LEP leptin (obesity homolog, mouse) Yes Yes 
AVIL advillin Yes Yes 
DKK2 dickkopf homolog 2 (Xenopus laevis) Yes Yes 
ARAP3 
 
Yes Yes 
YBX2 Y box binding protein 2 Yes No 
CEP250 centrosomal protein 250kDa Yes No 
RPS6KB2 
ribosomal protein S6 kinase, 70kDa, 
polypeptide 2 
Yes No 
STX3 syntaxin 3 Yes No 
NFKBIE 
nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, epsilon 
Yes No 
GSTO1 glutathione S-transferase omega 1 Yes No 
WT1 Wilms tumor 1 Yes No 
DYNC1I1 dynein, cytoplasmic 1, intermediate chain 1 Yes No 
RET 
ret proto-oncogene (multiple endocrine 
neoplasia and medullary thyroid carcinoma 1, 
Hirschsprung disease) 
Yes No 
TIPIN TIMELESS interacting protein Yes No 
LLGL2 lethal giant larvae homolog 2 (Drosophila) No Yes 
TG thyroglobulin No Yes 
DDIT4 DNA-damage-inducible transcript 4 No Yes 
HPCA hippocalcin No Yes 
GRAMD3 GRAM domain containing 3 No No 
PAX4 paired box gene 4 No No 
KCNJ4 
potassium inwardly-rectifying channel, 
subfamily J, member 4 
No No 
NPY neuropeptide Y No No 
CHRNA6 cholinergic receptor, nicotinic, alpha 6 No No 
FRAT2 
frequently rearranged in advanced T-cell 
lymphomas 2 
No No 
ERBB4 
v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian) 
No No 
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Results of GSEA of Involution Specific Signatures in TN subtype versus non-TN subtype in IBC 
Out of 10 gene signatures developed through STEM clustering using data from Clarkson et al. 
(2004), we found that no gene signature was significantly enriched in TN subtype versus non-TN subtype 
in IBC cases at FDR <25% or nominal p-value of 0.05 in both the training and validation sets. For 
involution specific signatures reported by Stein et al. (2009), we also did not find any gene signature that 
was significantly enriched in TN subtype versus non-TN subtype in IBC cases at FDR <25% or nominal 
p-value of 0.05 in both the training and validation sets (Table 8). 
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Table 8: GSEA results of involution-specific signatures in TN subtype versus non-TN subtype in 
IBC 
Gene 
Signature 
Results on Training Set Results on Validation Set 
Enriched 
in TN vs 
non-TN 
Size ES NES 
Nominal 
p-value 
FDR 
q-
value 
Enriched 
in TN vs 
non-TN 
Size ES NES 
Nominal 
p-value 
FDR 
q-
value 
Involution specific signatures developed through STEM clustering using data from Clarkson et al. 2004 
Inv1 Non-TN 205 -0.215 -0.620 0.906 1.000 TN 205 0.389 1.192 0.270 1.000 
Inv2 Non-TN 100 -0.256 -1.009 0.434 0.977 TN 100 0.183 0.718 0.818 0.863 
Inv3 Non-TN 57 -0.476 -1.362 0.039 0.271 Not-TN 57 -0.401 -1.162 0.217 0.856 
Inv4 TN 33 0.211 0.598 0.938 0.950 Not-TN 33 -0.295 -0.897 0.602 1.000 
Inv5 TN 30 0.336 1.029 0.391 1.000 Not-TN 30 -0.315 -0.837 0.785 0.692 
Inv6 TN 62 0.255 0.872 0.717 0.906 TN 62 0.269 0.915 0.632 0.652 
Inv7 Non-TN 36 -0.517 -1.371 0.077 0.515 Not-TN 36 -0.313 -0.871 0.717 0.849 
Inv8 Non-TN 24 -0.309 -0.962 0.485 0.847 TN 24 0.311 0.979 0.475 0.878 
Inv9 Non-TN 33 -0.281 -0.592 0.915 0.962 TN 33 0.431 0.959 0.528 0.707 
Inv10 Non-TN 21 -0.242 -0.719 0.827 1.000 TN 21 0.333 0.988 0.488 1.000 
Involution specific signatures reported in Stein et al. 2009 
S.C1 Non-TN 182 -0.23 -0.59 0.965 1 TN 182 0.43 1.13 0.31 1 
S.C2 Non-TN 205 -0.2 -0.56 0.969 0.989 Non-TN 205 -0.31 -0.9 0.605 1 
S.C3 Non-TN 252 -0.18 -0.59 0.937 1 TN 252 0.2 0.79 0.762 0.93 
S.C4 Non-TN 258 -0.29 -1.13 0.327 0.908 TN 258 0.17 0.76 0.787 0.832 
S.C5.I3VL7 Non-TN 117 -0.35 -1.28 0.116 1 Non-TN 117 -0.31 -1.08 0.349 0.933 
S.C6 Non-TN 100 -0.32 -1.12 0.31 0.696 TN 100 0.2 0.83 0.836 1 
S.C7 TN 225 0.23 0.93 0.572 0.472 Non-TN 225 -0.22 -0.8 0.822 0.729 
S.C8 Non-TN 153 -0.32 -1.19 0.149 1 Non-TN 153 -0.3 -1.12 0.243 1 
S.C9 Non-TN 66 -0.38 -1.11 0.301 0.497 TN 66 0.27 0.93 0.615 1 
S.I1VL7 Non-TN 495 -0.27 -1.12 0.275 0.558 Non-TN 495 -0.2 -0.88 0.676 1 
S.I2VL7 Non-TN 612 -0.26 -0.97 0.491 0.645 Non-TN 612 -0.21 -0.81 0.805 0.817 
S.I3VL7 Non-TN 648 -0.27 -1.01 0.446 0.64 Non-TN 648 -0.22 -0.84 0.745 0.911 
S.I4VL7 Non-TN 894 -0.25 -0.9 0.604 0.724 TN 894 0.22 0.88 0.653 1 
ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate; IBC, inflammatory 
breast cancer; TN, triple negative 
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Results of GSEA of Involution Specific Signatures in TN subtype versus non-TN subtype in non-
IBC 
Out of 10 gene signatures developed through STEM clustering using data from Clarkson et al. 
(2004), we found that no gene signature was significantly enriched in TN subtype versus non-TN subtype 
in non-IBC cases at FDR <25% or nominal p-value of 0.05 in both the training and validation sets. For 
involution specific signatures reported by Stein et al. (2009), we also did not find any gene signature that 
was significantly enriched in TN subtype versus non-TN subtype in non-IBC cases at FDR <25% or 
nominal p-value of 0.05 in both the training and validation sets (Table 9). 
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Table 9: GSEA results of involution-specific signatures in TN subtype versus non-TN subtype in 
non-IBC 
Gene 
Signature 
Results on Training Set Results on Validation Set 
Enriched 
in TN or 
non-TN 
Size ES NES 
Nominal 
p-value 
FDR 
q-
value 
Enriched 
in TN or 
non-TN 
Size ES NES 
Nominal 
p-value 
FDR 
q-
value 
Involution specific signatures developed through STEM clustering using data from Clarkson et al. 2004 
Inv1 Non-TN 205 -0.207 -0.621 0.926 0.945 TN 205 0.443 1.303 0.160 0.431 
Inv2 TN 100 0.193 0.740 0.731 1.000 TN 100 0.270 1.016 0.397 0.375 
Inv3 Non-TN 57 -0.328 -0.950 0.537 1.000 Non-TN 57 -0.289 -0.842 0.732 0.640 
Inv4 TN 33 0.228 0.693 0.864 1.000 TN 33 0.407 1.174 0.264 0.278 
Inv5 TN 30 0.385 1.166 0.159 1.000 Non-TN 30 -0.403 -1.059 0.388 0.674 
Inv6 TN 62 0.263 0.893 0.667 0.989 TN 62 0.365 1.260 0.108 0.364 
Inv7 Non-TN 36 -0.333 -0.923 0.583 0.795 TN 36 0.375 1.063 0.336 0.367 
Inv8 TN 24 0.361 1.093 0.356 0.666 TN 24 0.398 1.179 0.250 0.328 
Inv9 TN 33 0.308 0.689 0.843 0.868 TN 33 0.685 1.504 0.048 0.291 
Inv10 TN 21 0.384 1.138 0.284 0.825 TN 21 0.389 1.181 0.258 0.407 
Involution specific signatures reported in Stein et al. 2009 
S.C1 Non-TN 182 -0.24 -0.66 0.912 0.924 TN 182 0.55 1.47 0.047 0.302 
S.C2 Non-TN 205 -0.38 -1.16 0.297 1 TN 205 0.28 0.85 0.645 0.594 
S.C3 TN 252 0.16 0.62 0.933 0.952 TN 252 0.29 1.07 0.352 0.355 
S.C4 TN 258 0.22 0.87 0.597 1 TN 258 0.35 1.46 0.088 0.164 
S.C5.I3VL7 Non-TN 117 -0.28 -1.07 0.365 0.978 TN 117 0.26 0.97 0.477 0.456 
S.C6 TN 100 0.21 0.8 0.772 0.825 TN 100 0.28 1.12 0.271 0.34 
S.C7 TN 225 0.24 0.96 0.523 1 TN 225 0.22 0.9 0.621 0.539 
S.C8 Non-TN 153 -0.21 -0.78 0.883 1 Non-TN 153 -0.2 -0.77 0.902 0.774 
S.C9 TN 66 0.28 0.94 0.564 1 TN 66 0.3 0.98 0.467 0.485 
S.I1VL7 TN 495 0.2 0.86 0.7 0.845 TN 495 0.28 1.22 0.179 0.365 
S.I2VL7 Non-TN 612 -0.21 -0.85 0.684 1 TN 612 0.29 1.18 0.208 0.366 
S.I3VL7 Non-TN 648 -0.22 -0.87 0.652 1 TN 648 0.28 1.15 0.253 0.35 
S.I4VL7 Non-TN 894 -0.2 -0.75 0.845 0.924 TN 894 0.32 1.24 0.148 0.43 
ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate; IBC, inflammatory 
breast cancer; TN, triple negative 
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4 DISCUSSION 
 
We reanalyzed the previously published expression profiling data set obtained from mammary 
glands derived from mice at various stages of post-lactational mammary gland involution (12 gene 
expression profiles with two hybridizations for each of 10 day lactation time point, and 12, 24, 48, 72 and 
96 hour involution time points). We focused on genes that were differentially expressed during time 
periods spanning from the last day of lactation (day 10) to 4th day of involution by greater than 2 fold (P < 
0.05) and performed STEM cluster analysis to discern time varied expression patterns. We identified 10 
separate and significant time varied gene expression patterns of post-lactational mammary gland 
involution.  
 
Up to now, the two most comprehensive studies examining the global gene expression on the post-
lactational mammary gland involution have been conducted by Clarkson et al [4, 6] and Stein et al [5]. 
Clarkson et al [4] used the K means clustering method and Stein et al used the self-organizing map in [5] 
and the hierarchical ordered partitioning and collapsing hybrid (HOPACH) method in [10] to find the 
patterns among differentially expressed genes in the post-lactational involution period. They observed the 
induction of apoptotic pathways and immunomodulatory signals in the post-lactational involution. During 
our reanalysis, we used the STEM clustering method on the dataset by Clarkson et al [4] to find the time-
varied patterns among differentially expressed genes in the post-lactational involution period. We 
identified 10 separate and significant time varied expression patterns from 774 genes out of 1,055 
significantly differentially expressed genes. Gene ontology analyses of these clusters showed that cluster 
1, which represented genes showing gradual up-regulation during first 4 days of involution, had over-
representation of biological processes like fatty acid beta-oxidation, blood vessel morphogenesis, 
phagocytosis, response to interferon-gamma, humoral immune response mediated by circulating 
immunoglobulin, and regulation of cell motility.  Our findings of over-representation of biological 
processes are in general agreement with findings by Clarkson et al. [4] who used a different analytical 
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approach, and with findings by Stein et al. [5, 10] who used a different mouse system and a different 
analytical approach.  
 
We examined the enrichment of post-lactational mammary gland involution gene expression patterns 
in TN BC and IBC using the GSEA method. First, we used 10 significant time varied gene expression 
patterns that we found in the dataset from Clarkson et al [4].  We found that only 1 gene expression 
pattern was enriched in IBC compared to non-IBC in both training and validation sets at the nominal p-
value. None of these gene expression patterns was enriched in TN BC compared to non-TN BC for both 
IBC and non-IBC groups in both trading and validation sets. Second, we used 13 gene expression patterns 
on post-lactational involution as reported by Stein et al [10] and found that none of these gene expression 
patterns was significantly enriched in IBC compared to non-IBC and TN BC compared to non-TN BC in 
both training and validation sets. To further investigate, we examined the overlap between the involution-
specific signatures and the IBC-like signature (79 genes) [25]. We found that there was minimal overlap 
between the involution-specific signatures and the IBC-like signature and no gene overlapped between 
Inv5 signature and the IBC-like signature (Table 10). 
 
Major strength of our study is the use of the largest series of IBC samples ever reported by the World 
IBC Consortium and the novelty of our study is the use of updated Chip Definition Files from the  
BrainArray [30] during preprocessing of gene expression data for accurate probe mapping to the genome. 
Also, we used the gene set enrichment analysis (GSEA) [34] to examine enrichment of involution 
signatures in IBC and TN BC phenotype. The GSEA gives more statistical power to detect smaller 
changes in genes of a gene set compared to other methods of enrichment analysis. Major limitations of 
our study are cross-sectional analysis of enrichment of involution specific signatures in breast cancer and 
array-based measurement of gene expression profiles which limits the detection of differentially 
expressed genes with lower levels of expression. 
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One gene signature that showed enrichment in IBC compared to non-IBC contained genes that 
showed initial up-regulation and later down-regulation during the involution process. This might suggest 
that genes that up-regulate during an initial phase of involution after abrupt weaning might not be turning 
off and could be responsible for development of IBC like phenotype later in life. We examined the 
overlap of this gene expression pattern with the existing gene signatures using the Molecular Signatures 
Database (MSigDB) v4.0 which is available online at 
http://www.broadinstitute.org/gsea/msigdb/index.jsp [34]. We found that the genes up-regulated in 
vascular smooth muscle cells (VSMC) by c-Jun N-terminal protein kinase 1 (JNK1) [35] showed the most 
significant overlap (FDR q value = 6.07E-5). Among these overlapped genes, 3 genes - Involucrin (IVL), 
Cluster of Differentiation 79B (CD79B), and leptin (LEP) –were significantly enriched in IBC compared 
to non-IBC in both training and validation data sets in our analysis. Involucrin is a transglutaminase 
substrate protein present in keratinocytes of epidermis and other stratified squamous epithelia [36]. Tsuda 
et al (1997) investigated the expression of Involucrin in breast cancer and found that Involucrin 
expression was detected in 27% of breast cancer cases and was associated with high-grade atypia, a solid-
nest pattern, cancer cell necrosis on histology and negative oestrogen receptor status [37]. Leptin is a 
product of the obese (ob) gene, an important regulator of energy balance and necessary for normal 
mammary gland development [38]. In ER-positive breast cancer cell lines, leptin has been shown to 
stimulate cell growth through activation of multiple signaling pathways including the Janus Kinase/Signal 
Transducer and Activator of Transcription (JAK/STAT) pathway [39].   
 
 
 
  
36 
 
Table 10: Overlap of genes between involution-specific signatures and IBC-like signature 
 
Involution 
signature 
# Genes 
total 
# Genes 
overlapped 
with IBC-
like 
signature 
Symbols of Genes overlapped with IBC-like 
signature 
Clarkson et al. 
2004 
Inv1 256 1 MARCKS 
Inv2 118 2 ARPC2, HSP90B1 
Inv3 69 2 FOLR1, TMC6 
Inv4 47 0 
 Inv5 43 0 
 Inv6 76 1 DAB2 
Inv7 39 0 
 Inv8 31 0 
 Inv9 37 0 
 Inv10 26 0 
 
Stein et al. 
2009 
S.c1 242 1 PRKCB 
S.c2 262 1 HSP90B1 
S.c3 325 4 MARCKS, PNP, SP3, ZFR 
S.c4 343 7 
ACTG1, ARPC2, ATF2, IQGAP1, RYK, TBL1XR1, 
TNPO1 
S.c5.i3vl7 146 4 ACOX1, CTBP2, CTSA, IQGAP1 
S.c6 137 1 PAK2 
S.c7 282 2 DAB2, TMC6 
S.c8 212 3 BCKDK, DAB2, FOLR1 
S.c9 81 1 JMJD6 
S.i1vl7 643 7 
ACOX1, ARPC2, CTBP2, CTSA, FOLR1, IQGAP1, 
RYK 
S.i2vl7 790 10 
ACOX1, ARPC2, CTBP2, CTSA, DAB2, FOLR1, 
IQGAP1, PNP, RYK, TMCO1 
S.i3vl7 834 9 
ACOX1, ARPC2, CTBP2, CTSA, DAB2, FOLR1, 
HSP90B1, IQGAP1, RYK 
S.i4vl7 1160 14 
ACOX1, ARPC2, ATF2, BCKDK, CTBP2, CTSA, 
DAB2, FOLR1, IQGAP1, MARCKS, PNP, RYK, 
TMCO1, ZFR 
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5 CONCLUSION 
 
In summary, we have reanalyzed the previously published gene expression data set using the STEM 
clustering method and identified 10 separate and significant time-varied gene expression patterns for the 
abrupt post-lactational mammary gland involution. We found significant enrichment of one post-
lactational involution gene signature in IBC compared to non-IBC. This enriched signature represented 
genes showing initial up-regulation and later down-regulation during the involution process and there was  
significant overlap with genes up-regulated in vascular smooth muscle cells (VSMC) by c-Jun N-terminal 
protein kinase (JNK1). We identified three genes – Involucrin (IVL), Cluster of Differentiation 79B 
(CD79B), and leptin (LEP) – that were significantly enriched in IBC compared to non-IBC in both 
training and validation data sets and that are up-regulated in VSMC by JNK1. Our results suggest that 
these genes might be playing a role in IBC development. Whether or not this signature is upregulated in 
the normal tissues around IBC tumors and if breast feeding or abrupt cessation of breast feeding 
contributes to the persistence of this signature in the normal breast will be investigated in future studies. 
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